Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Infection » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Medicine Research Summaries. Volume 16
$195.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Inflammatory Conditions of the Colon
02.A Literature Review of the Practical Application of Bacteriophage Research
03.Bacterial Endocarditis: Etiology, Pathogenesis and Interventions
04.Eye Infections, Blindness and Myopia
05.The First Decade of Safe and Effective HIV Vaccines
06.Cytomegalovirus Infections: Risk Factors, Causes and Management
07.Emerging Geminiviral Diseases and their Management
08.Super-Spreading in Infectious Diseases
09.Helicobacter pylori: Detection Methods, Diseases and Health Implications
10.Development of New Antituberculosis Drugs
Notifications more
NotificationsNotify me of updates to Development of New Antituberculosis Drugs
Tell A Friend
 
Tell someone you know about this product.
Development of New Antituberculosis Drugs
Retail Price: $195.00
10% Online Discount
You Pay:

$175.50
Editors: W.W. Yew (Grantham Hospital, Hong Kong)
Book Description:
In the global war to control tuberculosis (TB), there are several critical battles which must be waged and won if we are to make significant progress. Broadly speaking, these battlefields may be regarded as diagnosis, treatment and prevention. Within the arena of treatment are various critical elements. Current drug regimens require 6 months to achieve predictable cures; it is essential that shorter regimens be developed to lessen nonadherence and to improve affordability.
To facilitate directly-observed therapy, intermittent (less than daily) regimens have been employed. To ensure favorable outcomes, including patients with AIDS, thrice-weekly regimens are the current standard; reducing the frequency of dosing to twice- or once-weekly may offer significant advantages.
Drug resistance to the current major medications, the rifamycins and isoniazid, threatens to make tuberculosis untreatable for rising numbers of patients in many regions of the world. Finding new, effective agents is essential to ensure cures for these cases and to halt transmission of multidrug-resistant tuberculosis to others.
Additional issues include reducing the side effects and toxicity of anti-tuberculosis regimens and developing regimens that can be given simultaneously with anti-retroviral therapy without deleterious drug-drug interactions or unacceptable toxicity.
Finally, attention must be directed to the potential utility of treating latent infection to prevent the evolution of active disease. The current vaccine Bacille Calmette-Guerin (BCG), while protecting infants and children against potentially lethal forms of TB, has done little to control the incidence of communicable adult pulmonary disease. Research is underway to develop improved vaccines, but due to the prolonged period to determine the efficacy of a TB vaccine (a minimum of 10 to 20 years)—alternative strategies must be pursued. Furthermore, the utility of a traditional vaccine would be sorely limited by the fact that roughly two billion persons today harbor latent tuberculosis infection. This huge reservoir of future disease would not be eligible for a traditional pre-infection vaccine.
“Preventive therapy” with isoniazid has been shown to reduce the subsequent risk of tuberculosis by about 70% in large, randomized placebo-controlled clinical trials. However, this strategy is limited by the requirement for extended duration of treatment (6 to 9 months), the risks of drug-induced hepatitis and rising rates of resistance to isoniazid in many regions of the world where the TB epidemic is most intense. Alternative means for the treatment of latent tuberculosis infection should be given high priority.
The authors have assembled an outstanding panel of contributors to address these issues. The topics herein have great relevance both in the industrialized nations where contemporary medications and strategies appear to have exacted their maximum benefits and for the developing nations where this ancient scourge remains rampant. This book will provide an impetus for authorities and organizations devoted to the development of new drugs to address the aforementioned growing problems of TB worldwide.

Table of Contents:
Chapter Availability

Individual chapters are available for $25 each by sending an email to novascience@earthlink.net. Nova will provide the chapter for your easy downloading or send it as an email attachment if you prefer.

Preface

1. GLOBAL CONTROL OF TUBERCULOSIS AND NEW DRUGS. Public health aspects of new drug development for tuberculosis; PP. 1-15
(Donald A. Enarson.)

2. GENOMICS IN THE FIGHT AGAINST MYCOBACTERIAL DISEASES; PP. 17-28
(Antoine Danchin.)

3. TARGET SELECTION TO SHORTEN THE COURSE OF TUBERCULOSIS CHEMOTHERAPY; PP. 29-52
(Clifton E. Barry 3rd, Helena I.M. Boshoff, Laura E. Via)

4. PHARMACOLOGICAL ISSUES IN THE DEVELOPMENT OF NEW ANTITUBERCULOSIS DRUGS; PP. 53-73
(Eric L. Nuermberger, Jacques H. Grosset, Charles A. Peloquin.)

5. THE MOUSE MODEL IN EVALUATION OF NEW ANTITUBERCULOSIS DRUGS: PROMISE AND LIMITATIONS; PP. 75-94
(Michael H. Cynamon and John T. Welch)

6. SURROGATE MARKERS TO ASSESS CLINICAL EFFICACY OF NEW ANTITUBERCULOSIS DRUGS; PP. 95-113
(Robert S. Wallis and John L. Johnson)

7. EARLY BACTERICIDAL ACTIVITY STUDIES: PROMISE AND PITFALLS; PP. 115-131
(Stephen H. Gillespie.)

8. ROLE OF CLINICAL TRIALS IN THE EVALUATION OF NEW ANTI-TUBERCULOSIS DRUGS; PP. 133-170
(Chi Chiu Leung and Cheuk Ming Tam)

9. CURRENT AND FUTURE USES OF RIFAMYCINS IN THE TREATMENT OF PULMONARY TUBERCULOSIS; PP. 171-202
(Andrew A. Vernon)

10. FLUOROQUINOLONES IN THE TREATMENT OF TUBERCULOSIS: CURRENT STATUS AND FUTURE ISSUES; PP. 203-237
(Wing Wai Yew, Chi Hung Chau, Michael D. Iseman)

11. MANAGEMENT OF LATENT TUBERCULOSIS INFECTION TODAY AND IN THE FUTURE; PP. 239-258
(Robert M. Jasmer and Charles L. Daley)

12. NOVEL DELIVERY SYSTEMS FOR ANTITUBERCULOSIS DRUGS; PP. 259-275
(Rajesh Pandey and Gopal K Khuller)

13. IMMUNOLOGY OF TUBERCULOSIS: IMPLICATIONS FOR THE DEVELOPMENT OF NEW THERAPIES AND VACCINES; PP. 277-300
(Graham A.W. Rook and Keertan Dheda)

Index

   Binding: Hardcover
   Pub. Date: 2006
   ISBN: 1-59454-857-9
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Customers who bought this product also purchased
Tropical Anemia
Tropical Anemia
The Adolescent Today in Medicine
The Adolescent Today in Medicine
Recent Advances in HIV Infection Research
Recent Advances in HIV Infection Research
New Developments in Epstein-Barr Virus Research
New Developments in Epstein-Barr Virus Research
Cardiovascular Health and Disease Research Trends
Cardiovascular Health and Disease Research Trends
Progress in Medical Genetics
Progress in Medical Genetics
Special Focus Titles
01.Essureal Journey: Concepts, Concerns and Considerations for Hysteroscopic Sterilization
02.Feminism: Past, Present and Future Perspectives
03.Accelerating Newborn through Toddler Learning Development
04.Neonatal Intensive Care Units (NICUs): Clinical and Patient Perspectives, Levels of Care and Emerging Challenges
05.Genetic Mistakes: Understanding and Living with Fatty Acid Oxidation Disorders
06.The Impact of Severe Mental Illness on Quality of Life: Challenges for Research and Practices
07.Vukhomba: An Analysis of the Puberty Rites of Passage for Girls among Vatsonga in Relation to Sexuality Education
08.The Challenges and Issues of Tourism Development in China
09.Reconstruction of the Tradition: Tourism and Authentication of Heritage in China
10.Nonlinearity: Problems, Solutions and Applications. Volume 1
11.Adaptive Management: Elements, Applications and Research
12.Natural Fibers: Properties, Mechanical Behavior, Functionalization and Applications

Nova Science Publishers
© Copyright 2004 - 2017

Development of New Antituberculosis Drugs